The model’s validity was further verified using breast cancer cells overexpressing metastasis-specific genes (CXCR4, claudin-2, Linc-ZNF469-3) and a patient-derived organoid (PDO) from a patient with advanced metastatic disease. The gene discussed is CLDN2; the disease is breast cancer.